More recently, p300/CBP inhibition has been shown to decrease secretion of exosomal PD-L1 by tumour cells, suggesting that the combination of HAT inhibitors with immune checkpoint inhibitors could play a synergic role and improve therapeutic efficacy [76]. The gene discussed is EP300; the disease is neoplasm.